Dhampur Bio Organics Q1 FY27 Results: Net Profit ₹38.40 Cr, Appoints Grant Thornton as Internal Auditor
Dhampur Bio Organics reported Q1 FY27 standalone net profit of ₹38.40 Crore and consolidated net profit of ₹36.79 Crore. The company appointed Grant Thornton Bharat LLP as Internal Auditor for FY27. It also completed the sale of its Meerganj unit for ₹305 Crore, recognizing a gain of ₹63.89 Crore.
The improved financial performance and the strategic sale of an undertaking are material events that will significantly impact the company's financial position and future operations.
The company reported improved financial results for the quarter, with a significant turnaround from a loss to a profit, and also completed a strategic asset sale with a considerable gain.
Dhampur Bio Organics Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company's Board of Directors, in a meeting held on July 14, 2026, approved these results. The standalone net profit for the quarter stood at ₹38.40 Crore, a significant increase compared to a loss of ₹19.37 Crore in the corresponding quarter of the previous year. Consolidated net profit also rose to ₹36.79 Crore from a loss of ₹22.00 Crore in the same period last year.
The company decided not to declare an interim dividend. Furthermore, M/s Grant Thornton Bharat LLP was appointed as the Internal Auditor for the financial year 2026-27. The board meeting commenced at 11:40 AM and concluded at 12:25 PM IST.
In a significant development, Dhampur Bio Organics completed the sale of its Meerganj sugar manufacturing undertaking on a slump sale basis for an aggregate consideration of ₹305.00 Crore. This sale, approved by shareholders in an EGM on May 18, 2026, resulted in a gain of ₹63.89 Crore and became effective from June 18, 2026. The operations of the Meerganj unit have been classified as discontinued operations for all presented periods.
What to do with a filing like this
Dhampur Bio Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dhampur Bio Organics Limited. Read the original for the full detail.